HGH Fragment 176-191

HGH Fragment 176-191 is a synthetic modified peptide derived from the C-terminal region of the human growth hormone molecule. Specifically, this truncated sequence was engineered as a selective lipolytic agent, designed to isolate the fat-burning properties of growth hormone while removing the growth-promoting and diabetogenic effects associated with the intact molecule.

Mechanistically, research has focused on the fragment’s interaction with $\beta$-adrenergic receptors in adipose tissue. Consequently, studies show that it stimulates lipolysis—the enzymatic breakdown of stored triglycerides—while simultaneously inhibiting lipogenesis to prevent new lipid accumulation.

In addition, researchers have investigated its secondary metabolic effects, including improvements in insulin sensitivity and favorable adjustments to carbohydrate regulation. In contrast to full-length , the 176-191 fragment lacks the N-terminal region responsible for IGF-1 receptor binding and systemic cell proliferation. Overall, this precise structural isolation makes  targeted tool for researchers studying obesity biology, adipose pharmacology, and growth hormone fragment signaling.